Nautilus Biotechnology, Inc.
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$59.0M
- Total assets
- $191.1M
- Market cap
- $303.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating expenses
- $66.8M
- Income tax
- $0
- Net income
- -$59.0M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $191.1M
- Current assets
- $106.0M
- Total liabilities
- $34.1M
- Current liabilities
- $8.0M
- Shareholders’ equity
- $157.0M
Cash flow
- Operating cash flow
- -$50.7M
- Investing cash flow
- $35.2M
- Financing cash flow
- $214.0K
- Net cash flow
- -$15.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $303.7M
- EPS (diluted)
- $-0.47
- Shares outstanding
- 134.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 10, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $59.0M.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nautilus Biotechnology, Inc..
Write a review
News about Nautilus Biotechnology, Inc.
News & sentiment via Polygon.io
